TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04989803: Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

Sponsor: Kite, A Gilead Company · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 247 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,023,790

Rescue Site Savings

+$2,002,770

Unlock Full NCT04989803 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04989803 Rescue Dossier →